Carbamazepine Tablets recall
FDA recall D-0771-2026 · initiated Aug 7, 2026
Golden State Medical Supply Inc. recalled Carbamazepine Tablets in Aug 2026 — an FDA Class II recall (D-0771-2026) because CGMP deviations: tablets with black specks.
May cause temporary or medically reversible harm; low probability of serious harm.
Why it was recalled
CGMP deviations: tablets with black specks.
The manufacturing process itself
The FDA found the process itself out of compliance, usually before any defective product was identified.
This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.
Is your product affected? Check the lot number
A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.
Quantity recalled: 1200 bottles
Details
- Product
- Carbamazepine Tablets, USP, 200mg, packaged in a)1000-count bottles (NDC 51407-215-10), b) 100-count bottles (NDC 51407-215-01), Rx Only, Manufactured by: Taro Pharmaceutical Industries Ltd., Marketed by: GSMS, Incorporated, Camarillo, CA 93012 USA
- Recalling company
- Golden State Medical Supply Inc.
- Classification
- Class II
- Status
- Ongoing
- Type
- Voluntary: Firm initiated
- Distribution
- USA Nationwide
- Initiated
- Aug 7, 2026
- FDA report date
- Aug 26, 2026
Frequently asked
- Was Carbamazepine Tablets recalled?
- Golden State Medical Supply Inc. recalled Carbamazepine Tablets in Aug 2026 — an FDA Class II recall (D-0771-2026) because CGMP deviations: tablets with black specks. May cause temporary or medically reversible harm; low probability of serious harm.
- Why was Carbamazepine Tablets recalled?
- Per the FDA enforcement record, the reason for recall D-0771-2026 was: CGMP deviations: tablets with black specks.
- Is a recalled Carbamazepine Tablets dangerous to take?
- An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
- Which lots of Carbamazepine Tablets are affected?
- Distributed: USA Nationwide. The recall covers these lots — Lot #: a) GS067429, GS068091, Exp 5/31/2028; b) GS067430, GS068090, Exp 5/31/2028. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0771-2026.